TY - JOUR
T1 - Correction to
T2 - SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022) (Clinical and Translational Oncology, (2023), 25, 9, (2679-2691), 10.1007/s12094-023-03216-3)
AU - García-Campelo, Rosario
AU - Sullivan, Ivana
AU - Arriola, Edurne
AU - Insa, Amelia
AU - Juan Vidal, Oscar
AU - Cruz-Castellanos, Patricia
AU - Morán, Teresa
AU - Reguart, Noemí
AU - Zugazagoitia, Jon
AU - Dómine, Manuel
N1 - Publisher Copyright:
© 2023, The Author(s).
PY - 2023/9
Y1 - 2023/9
N2 - In Table 3 of this article, for the point "Second-line treatment in ES-SCLC", the statement "At the time of writing guideline document, lurbinectedin is FDA and EMA approved but not authorized in Spain" was incorrect but it should have been "At the time of writing guideline document, lurbinectedin is FDA approved, has granted orphan drug designation by the EMA, but not authorized in Spain." The corrected Table 3 is provided below.
AB - In Table 3 of this article, for the point "Second-line treatment in ES-SCLC", the statement "At the time of writing guideline document, lurbinectedin is FDA and EMA approved but not authorized in Spain" was incorrect but it should have been "At the time of writing guideline document, lurbinectedin is FDA approved, has granted orphan drug designation by the EMA, but not authorized in Spain." The corrected Table 3 is provided below.
UR - http://www.scopus.com/inward/record.url?scp=85167349845&partnerID=8YFLogxK
U2 - 10.1007/s12094-023-03290-7
DO - 10.1007/s12094-023-03290-7
M3 - Article
C2 - 37556098
AN - SCOPUS:85167349845
SN - 1699-048X
VL - 25
SP - 2760
EP - 2762
JO - Clinical and Translational Oncology
JF - Clinical and Translational Oncology
IS - 9
ER -
